Pharming Group reports on results of the 2023 Annual General Meeting of Shareholders - Yahoo Finance
PHARM Stock | EUR 0.83 0.02 2.35% |
About 61% of Pharming Group's investor base is looking to short. The analysis of current outlook of investing in Pharming Group NV suggests that many traders are alarmed regarding Pharming Group's prospects. The current market sentiment, together with Pharming Group's historical and current headlines, can help investors time the market. In addition, many technical investors use Pharming Group NV stock news signals to limit their universe of possible portfolio assets.
Pharming |
Pharming Group reports on results of the 2023 Annual General Meeting of Shareholders Yahoo Finance
Read at news.google.com
Pharming Group Fundamental Analysis
We analyze Pharming Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharming Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharming Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Pharming Group is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Pharming Group NV Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pharming Group stock to make a market-neutral strategy. Peer analysis of Pharming Group could also be used in its relative valuation, which is a method of valuing Pharming Group by comparing valuation metrics with similar companies.
Peers
Pharming Group Related Equities
BAMNB | Koninklijke BAM | 5.01 | ||||
GLPG | Galapagos | 0.78 | ||||
PNL | PostNL NV | 1.94 | ||||
FUR | Fugro NV | 2.24 | ||||
AMG | AMG Advanced | 3.42 |
Complementary Tools for Pharming Stock analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |